Subscribe to the Novartis Oncology RSS Newsfeed to Receive Novartis Oncology Press Releases http://www.novartisoncology.com <![CDATA[FDA approves Novartis drug Glivec® label recommending extending treatment to three years for certain GIST patients after surgery]]> 2012-02-01T07:15:00 CET http://www.novartisoncology.com/media/press-releases.jsp?id=1581641&year=2012 <![CDATA[CHMP recommends EU approval to update Novartis drug Glivec® label to include three year treatment for GIST patients after surgery]]> 2012-01-20T15:43:58 CET http://www.novartisoncology.com/media/press-releases.jsp?id=1579137&year=2012 <![CDATA[Novartis pivotal study of Exjade® shows significant reduction of iron overload in patients with non-transfusion-dependent thalassemia]]> 2011-12-13T17:30:00 CET http://www.novartisoncology.com/media/press-releases.jsp?id=1571098&year=2011 <![CDATA[New Phase III data shows Novartis JAK inhibitor INC424 significantly reduced disease burden in patients with myelofibrosis]]> 2011-12-13T01:30:00 CET http://www.novartisoncology.com/media/press-releases.jsp?id=1570771&year=2011 <![CDATA[Two Novartis Phase III studies show twice as many Ph+ CML patients achieve deeper levels of response with Tasigna® compared to Glivec®]]> 2011-12-12T23:45:00 CET http://www.novartisoncology.com/media/press-releases.jsp?id=1570773&year=2011 <![CDATA[New data confirms Novartis drug Afinitor® significantly extends time women with advanced breast cancer live without tumor growth]]> 2011-12-08T00:30:00 CET http://www.novartisoncology.com/media/press-releases.jsp?id=1569858&year=2011 <![CDATA[Novartis highlights advances for patients with breast cancer and hematological diseases with over 160 SABCS and ASH abstracts]]> 2011-12-02T07:15:00 CET http://www.novartisoncology.com/media/press-releases.jsp?id=1568356&year=2011 <![CDATA[Novartis drug Afinitor® helps women with advanced breast cancer live significantly longer without their disease progressing]]> 2011-09-26T00:01:00 CET http://www.novartisoncology.com/media/press-releases.jsp?id=1549523&year=2011 <![CDATA[Novartis drug Afinitor® effective in patients with non-cancerous kidney tumors associated with TSC in Phase III trial]]> 2011-09-23T17:30:00 CET http://www.novartisoncology.com/media/press-releases.jsp?id=1549360&year=2011 <![CDATA[Novartis receives EU approval for Votubia®, the first medication to treat children and adults with SEGA associated with TSC]]> 2011-09-08T07:15:00 CET http://www.novartisoncology.com/media/press-releases.jsp?id=1544915&year=2011